Jürgen Semmler Announced as New Shimadzu Europe Managing Director
Shimadzu (Duisburg, Germany) has appointed Jürgen Semmler as the new Managing Director of its European organization from 1 July 2021. Previously head of Shimadzu Deutschland, he succeeds Jürgen Kwass, who led Shimadzu Europa from 2003 to the present and is now retiring.
Jürgen Semmler graduated in chemical engineering at Essen University, Germany, before joining Shimadzu in 1987 as an HPLC service engineer. He gained international experience as a European team member in the development of a global software and since 1996 as manager of the European Customer Support Centre. In 2006, he was appointed Managing Director of the newly founded Shimadzu Deutschland. Under his management, the company has grown from 60 to more than 150 employees, and its sales from €19m to over €40m. Previously independent companies were incorporated into the organization as technical offices under the overall management of Shimadzu Deutschland.
“Under Jürgen Kwass’ aegis, Shimadzu’s network was rolled out to every European country and set up structurally and in terms of staff to serve the customer needs of medium-sized companies as well as global players. Shimadzu’s growth is closely linked to his commitment and name,” said Jürgen Semmler.
For more information please visit: www.shimadzu.de
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
